Mannosylated nanoparticulate carriers of rifabutin for alveolar targeting

Nimje, Navneet; Agarwal, Abhinav; Saraogi, Gaurav Kant; Lariya, Narendra; Rai, Gopal; Agrawal, Himanshu; Agrawal, Govind P.

doi:10.3109/10611860903115308

Cited by 123 publications

(51 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is more challenging for delivery of drugs to central nervous system (CNS) and brain but NPs and neuropeptides can over comes these problems and the drug can be delivered in the brain successfully through the carrier such as hexapeptide dalargin, dipeptide kyotorphin across blood brain barriers (BBB) through endocytosis by endothelical cell lining of the brain blood capillaries. Nimje [59] impart that NPs can be used as carrier such as mannose conjugated solid lipid NPs (SLNPs) that can be exploited for effective and targeted delivery of rifabutin. [60].…”

Section: Microencapsulation Of Nanoparticlesmentioning

confidence: 99%

Nanoparticles in Drug Delivery and Cancer Therapy: The Giant Rats Tail

Prabhu¹,

Uzzaman²,

Grace³

et al. 2011

JCT

View full text Add to dashboard Cite

show abstract

Section: Microencapsulation Of Nanoparticlesmentioning

confidence: 99%

Nanoparticles in Drug Delivery and Cancer Therapy: The Giant Rats Tail

Prabhu¹,

Uzzaman²,

Grace³

et al. 2011

JCT

View full text Add to dashboard Cite

show abstract

“…Similar results have been observed by others, studying conjugation of mannose onto SLNs, polypropyleneimine dendrimers, etc. [243][244][245].…”

Section: Macrophage Targetingmentioning

confidence: 99%

A New Era of Pulmonary Delivery of Nano-antimicrobial Therapeutics to Treat Chronic Pulmonary Infections

Merchant

Buckton²,

Taylor³

et al. 2016

CPD

View full text Add to dashboard Cite

Pulmonary infections may be fatal especially in immunocompromised patients and patients with underlying pulmonary dysfunction, such as those with cystic fibrosis, chronic obstructive pulmonary disorder, etc. According to the WHO, lower respiratory tract infections ranked first amongst the leading causes of death in 2012, and tuberculosis was included in the top 10 causes of death in low income countries, placing a considerable strain on their economies and healthcare systems. Eradication of lower respiratory infections is arduous, leading to high healthcare costs and requiring higher doses of antibiotics to reach optimal concentrations at the site of pulmonary infection for protracted periods. Hence direct inhalation to the respiratory epithelium has been investigated extensively in the past decade, and seems to be an attractive approach to eradicate and hence overcome this widespread problem. Moreover, engineering inhalation formulations wherein the antibiotics are encapsulated within nanoscale carriers could serve to overcome many of the limitations faced by conventional antibiotics, like difficulty in treating intracellular pathogens such as mycobacteria spp. and salmonella spp., biofilmassociated pathogens like Pseudomonas aeruginosa and Staphylococcus aureus, passage through the sputum associated with disorders like cystic fibrosis and chronic obstructive pulmonary disorder, systemic side effects following oral/parenteral delivery and inadequate concentrations of antibiotic at the site of infection leading to resistance. Encapsulation of antibiotics in nanocarriers may help in providing a protective environment to combat antibiotic degradation, confer controlled-release properties, hence reducing dosing frequency, and may increase uptake via specific and non-specific targeting modalities. Hence nanotechnology combined with direct administration to the airways using commercially available delivery devices, is a highly attractive formulation strategy to eradicate microorganisms from the lower respiratory tract, which might otherwise present opportunities for multi-drug resistance.

show abstract

“…Results of in vivo toxicity studies showed that capreomycin oleate exhibited its lowest toxic potential suggesting it be used as super generics in pulmonary tuberculosis treatment [73]. Outcomes of various miscellaneous lipid based drug delivery systems in the treatment of TB are summarized in Table 6 [74][75][76][77][78][79][80][81][82][83][84][85][86].…”

Section: Miscellaneous Lipid Based Formulationsmentioning

confidence: 99%

Exploring the Use of Lipid Based Nano-Formulations for the Management of Tuberculosis

Cm¹,

Cd²,

M³

et al. 2017

J Nanosci Curr Res

View full text Add to dashboard Cite

Tuberculosis (TB) is an airborne infectious disease spreading very fast from person to person, which affect the health as well as socioeconomic conditions harshly. Though varieties of antitubercular drugs (ATDs) are available for its treatment, associated stern side effects restrict the patients to receive complete therapeutic benefits. Moreover, emergence of drug-resistant tuberculosis and co-infection of TB with HIV further worsen the situations. Polymeric formulations are introduced for progressive and long-term delivery of therapeutic agents, but owing to their noted limitations, performance is not up to the mark. In this juxtaposition, lipid based nano-formulations are introduced as an alternative to the polymic formulations in the management of TB with an intention to overcome side effects related to drugs along with limitations of polymeric formulations. The lipid based formulations comprise nanoemulsions, solid-lipid nanoparticles (SLNs), nano-structured lipid carriers (NLCs), liposomes, and niosomal systems, etc.Liposomes have more promising antitubercular activity as its intended for targeted drug delivery especially to the infected part. Further mannosylation of liposomes offers tremendous results in TB chemotherapy as it directly binds to mannose receptors available on the surface of alveolar macrophages resulting mycobacterium destruction. Niosomes may have superior drug targeting ability, chemical stability, osmotic activeness and in vivo activity in comparison to that of liposomes. SLNs and manosylated SLNs are the advanced form of the lipid formulations which enhance the drug uptake at the infected organ and show significant in vivo anti-tubercular activity with reduced toxicity. Moreover, NLCs shows its satisfactory potential against MTb along with drug targeting action. Advancement on the development of miscellaneous or other vesicular lipid formulations are not encouraging in the field of tubercular chemotherapy. Hence, lipid based formulations could be successfully employed for targeted delivery of ATDs with promising anti-tubercular activity.

show abstract

Mannosylated nanoparticulate carriers of rifabutin for alveolar targeting

Cited by 123 publications

References 28 publications

Nanoparticles in Drug Delivery and Cancer Therapy: The Giant Rats Tail

Nanoparticles in Drug Delivery and Cancer Therapy: The Giant Rats Tail

A New Era of Pulmonary Delivery of Nano-antimicrobial Therapeutics to Treat Chronic Pulmonary Infections

Exploring the Use of Lipid Based Nano-Formulations for the Management of Tuberculosis

Contact Info

Product

Resources

About